InvestSMART

Microba Life Sciences Limited (ASX:MAP)

ALERT: Price-sensitive ASX Announcement for MAP
Current share price for MAP : $0.045 0.004 (9.76%)+
Announcement
Release
16 Jul 2026 9:03AM
Price at Release
$0.041
Full Release
download
Summary
Microba Life Sciences Limited reported strong growth in Q4 FY26, achieving a record core testing revenue of $2.53 million, up 45% year-on-year. The company sold approximately 22,400 core tests throughout the year, marking a 78% increase from FY25. Microba's focus on its core testing and high-margin Invivo supplement products contributed to a 53% rise in continuing product revenue. The phase-out of legacy products was reflected in a 6% decline in total annual revenue to $14.78 million. The company's strategic transition towards a streamlined operation and cost reduction initiatives are expected to save over $7 million annually by H1 FY27. Key financial highlights include total cash receipts of $3.95 million and a cash balance of $7.95 million as of June 30, 2026. Microba's lead therapeutic asset, MAP-315, is progressing towards a Phase 2 trial for ulcerative colitis.
Key Points
  • Record core testing revenue in Q4 FY26 of $2.53 million.
  • 22,400 core tests sold in FY26, a 78% increase from FY25.
  • Continuing product revenue grew 53% despite overall revenue decline.
  • Cost reduction initiatives to save over $7 million annually by H1 FY27.
  • MAP-315 asset progressing towards Phase 2 trial for ulcerative colitis.
  • Cash balance of $7.95 million as of June 30, 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.